Research Portfolio

FDA-NIH Research Portfolio

This list contains grants and contracts carried over from prior fiscal years and new projects awarded in the current fiscal year for Special Research Priority on U.S. Food and Drug Administration (FDA) Tobacco Product Regulation.

Investigator Initiated, FY12
Program Projects Administrative Supplements, FY12
R01 Competitive Revisions, PAR-12-010, FY12
U01 Competitive Revisions, PAR-12-011, FY12
Communication Administrative Supplements, FY12
Administrative Supplements, NOT-CA-10-007, FY10
Contracts supported by FDA Center for Tobacco Products

Investigator Initiated for Special Research Priority on U.S Food and Drug Administration (FDA) Tobacco Product Regulation funded in fiscal year 2012.

Principal Investigator Organization	Title	Grant Number
Blalock, J. Edwin University of Alabama at Birmingham	PGP, A Possible Biomarker for COPD Exacerbations and or Progression	1R01HL114439-01
Clark, Pamela I. University of Maryland College Park Campus	Rapid response human testing of smokeless tobacco products	1R01DA031142-01A1
Crystal, Ronald G Weill Medical College of Cornell University	COPD Metabolome, Smoking Oxidants and Aberrant Ciliated Cell Function	1P20HL113443-01
Cummings, K. Michael Medical University of South Carolina	Effectiveness of tobacco control policies in high vs. low income countries	3P01CA138389-05S1 (Admin Supplement)
Delnevo, Cristine D. University of Medicine and Dentistry of New Jersey School of Public Health	Measurement of Tobacco Use among South Asians in the U.S	1R21CA164913-01A1
Donny, Eric Christian University of Pittsburgh at Pittsburgh	Evaluating New Nicotine Standards for Cigarettes	5U54DA031659-02
Gordon, Sydney Michael Battelle Centers/Public Health Research and Evaluation	Real-Time Measurement and Uptake of Carcinogens by Menthol Cigarette Smokers	5R01CA162085-02
Hatsukami, Dorothy K. University of Minnesota Twin Cities	Models For Tobacco Product Evaluation	1U19CA157345-01A1
Mays, Darren M. Georgetown University	Framing Messages for Teen Smoking Prevention in Primary Care	1R03CA162839-01A1
Nasim, Aashir Virginia Commonwealth University	Cigarillo smoking: smoke toxicant content and user toxicant exposure and effects	R21CA161317-01A1
Pickworth, Wallace Bruce Battelle Centers/Public Health Research and Evaluation	Mainstream Smoke Composition and Toxin Exposure from Prototypical Cigar Products	1R01CA158045-01A1
Rice, Virginia Hill Wayne State University	Health Effects of Adolescent Water Pipe Smoking with & without Cigarette Smoking	1R15DA032822-01
Romer, Daniel University of Pennsylvania	Communicating Smoking Risks Through Graphic Warning Labels	1R01CA157824-01A1
Sterling, Kymberle L. Georgia State University	Developing Measures of Little Cigar Use for Young Adults	1R03CA159909-01A1
Timberlake, David University of California Irvine	Should Smokeless Tobacco be Promoted as an Alternative for Smokers ?	1R03DA027950-01A1
Trumbo, Craig W. Colorado State University Fort Collins	Social Normative Conditions and the Diffusion of Electronic Nicotine Delivery Sys	1R03DA033578-01
Van Der Vliet, Albert University of Vermont and State Agriculture College	Cigarette Smoke-derived Electrophilic Aldehydes and Airway Inflammation	1R01ES021476-01
Williams, Rebecca S. University of North Carolina Chapel Hill	Evaluating the Impact of Federal Legislation on Internet Tobacco Sales	1R01CA169189-01
Zou, Ming-Hui University of Oklahoma Health Sciences Center	AMPK as a redox sensor and modulator	2R01HL089920-05

Program Projects Administrative Supplements for Special Research Priority on U.S Food and Drug Administration (FDA) Tobacco Product Regulation, NOT-CA-12-007, funded in fiscal year 2012.

The grant titles and research descriptions reflect the parent awards. We are in the process of updating this content with the tobacco regulatory research being conducted through the administrative supplement.

Principal Investigator Organization	Title	Grant Number
Carroll, Kathleen Yale University	Psychotherapy Development Research Center	3P50DA009241-19S1
Fiore, Michael & Baker, Tim University of Wisconsin	Engineering Effective Interventions for Tobacco Use	3P50CA143188-14S1
Guydish, Joseph University of California San Francisco	Treatment for Complex Patients: Continuing and Extended Care	3P50DA009253-18S1
Malhotra, Anil Feinsein Institute for Medical Research	Dissecting Heterogeneity of Treatment Response of First Episode Schizophrenia	3P50MH080173-05S2
Mermelstein, Robin University of Illinois and Chicago	Social-Emotional Contexts of Adolescent Smoking Patterns	3P01CA098262-08S1
Murry, Charles University of Washington	Stem Cells and Cardiovascular Repair	3P01HL094374-03S1
Ziegler, Steven Benaroya Institute	Regulation of pulmonary inflammation by leukocytes and extracellular matrix	3P01HL098067-03S1

R01 Competitive Revisions for Special Research Priority on U.S Food and Drug Administration (FDA) Tobacco Product Regulation, PAR-12-010, funded in fiscal year 2012.

Principal Investigator Organization	Title	Grant Number
Andrews, Judy A Oregon Research Institute	Childhood and Adolescent Predictors of Substance Abuse in Emerging Adulthood	3R01DA010767-14S2
Chassin, Laurie Arizona State University Tempe Campus	Teen & Adult Smoking: Intergenerational Transmission and Prevention Applications	3R01DA13555-30S1
Crystal, Ronald G. Weill Medical College of Cornell University	Overlapping Airway Basal Cell Transcriptome Reprogramming in COPD and Lung Cancer	3R01HL107882-2S1
Ding, Xinxin Wadsworth Center	Human CYP2A and respiratory tract xenobiotic toxicity	3R01CA92596-9S1
Haddock, Christopher Keith National Development and Research Institutes	Barriers to Effective Tobacco Control Policy Implementation in the US Military	3R01CA109153-7S1
Hecht, Stephen S. University of Minnesota Twin Cities	Metabolism of Carcinogenic Tobacco-Specific Nitrosamines	3R37CA81301-14S1
Jordt, Sven-Eric Yale University	Counter-irritation by Menthol: Molecular Targets and Role in Airway Disease	3R01HL105635-02S1
Klesges, Robert C. University of Tennessee Health Science Center	Predictors of Smokeless Tobacco and Dual Use in the US Military	3R01CA141567-4S1
Latkin, Carl A. Johns Hopkins University	A comprehensive approach to secondary HIV prevention and care among positives	3R01DA32217-2S1
Turesky, Robert J. Wadsworth Center	2-Amino-9H-pyrido[2,3-b]indole: a potential colorectal carcinogen formed in tobacco	3R01CA134700-3S1
Wewers, Mary Ellen Ohio State University	Tobacco cessation interventions with Ohio Appalachian smokers	3R01CA129771-03S1
Wolfson, Mark Wake Forest University Health Sciences	Smokeless Tobacco Use in College Students	3R01CA141643-4S2

U01 Competitive Revisions for Special Research Priority on U.S Food and Drug Administration (FDA) Tobacco Product Regulation, PAR-12-011, funded in fiscal year 2012.

Principal Investigator Organization	Title	Grant Number
Bailey, William C. University of Alabama at Birmingham	Who and Why cigarette smokers use e-cigarettes after hospitalization	3U01DA31515-3S1
Dubinett, Steven M. University of California Los Angeles	The UCLA - Boston University Lung Cancer Biomarker Development Laboratory	3U01CA152751-3S1
Lerman, Caryn University of Pennsylvania	Pharmacogenetics of Nicotine Addiction Treatment	3U01DA20830-8S1

Communication Administrative Supplements for Special Research Priority on U.S. Food and Drug Administration (FDA) Tobacco Product Regulation funded in fiscal year 2012.

We are in the process of updating the content with the tobacco regulatory research being conducted through the administrative supplement.

Principal Investigator Organization	Title	Grant Number
Hornik, Robert University of Pennsylvania	Supporting the diffusion of the tobacco graphic warning labels	3P20CA095856-09S1
Kreuter, Matthew W. Washington University in St. Louis	Understanding reactions to graphic warning labels on cigarettes in diverse populations of youth and young adults at increased risk of smoking	3P50CA095815-09S1
Williams, David R. Harvard University	Assessing and Magnifying the Impact of Cigarette Pack Health Warnings among Vulnerable Populations: An Integrated Study	3P50CA148596-03S1

Administrative Supplements for Special Research Priority on U.S. Food and Drug Administration (FDA) Tobacco Product Regulation, NOT-CA-10-007, funded in fiscal year 2010.

Principal Investigator Organization	Title	Grant Number
Connolly, Gregory N. Harvard School of Public Health	Subjective and Behavioral Responses to PREP Design and Marketing: Modification of risk perceptions of light cigarettes	3R01CA125224-03S1
Cummings, K. Michael Roswell Park Cancer Institute	Effectiveness of Tobacco Control Policies in High vs. Low Income Countries	3P01CA138389-02S
Fong, Geoffrey T. University of Waterloo	International Tobacco Policy Surveys	3R01CA100362-05S1
Forster, Jean University of Minnesota	The Effects of Minnesota State and Local Programs on Young Adult Tobacco Use	3R01CA086191-10A1S1
Hatsukami, Dorothy K. University of Minnesota	Novel Determinants of Measures of Smokeless Tobacco Use	3R01CA141531-02S1
Henriksen, Lisa A. Stanford University	Impact of Retail Tobacco Advertising on Youth Smoking	3R01CA067850-10A1S1
Ling, Pamela M. University of California San Francisco	Understanding Smokeless Tobacco Marketing	3R01CA141661-02S1
Strasser, Andrew A. Stanford University	Smoking Topography and Harm Exposure in a New PREP	3R01CA120594-04S1

These contracts are also supported by the FDA CTP.

Population Assessment of Tobacco and Health (PATH) Study
In October 2011, the Food and Drug Administration (FDA) and the National Institutes of Health (NIH) announced a joint national, prospective, longitudinal cohort study of tobacco users and those at risk for tobacco-product use to monitor and assess their tobacco use and the resultant health impacts. The initiative, called the Population Assessment of Tobacco and Health (PATH) Study, represents the first large-scale NIH-FDA collaboration on tobacco regulatory research since Congress granted FDA the authority to regulate tobacco products under the Family Smoking Protection and Tobacco Control Act (FSPTCA). Scientific experts at the National Institute on Drug Abuse (NIDA) and FDA’s Center for Tobacco Products (CTP) will coordinate this effort via a research contract awarded to Westat in Rockville, MD.

The PATH Study will prospectively follow almost 60,000 people who are users of tobacco products and those at risk for tobacco-product use ages 12 and older in the United States. The study will a) examine what makes people susceptible to tobacco-product use; b) evaluate initiation and use patterns including use of new products, dual use, poly use, and switching of tobacco products; c) study patterns of tobacco-product cessation and relapse ; d) evaluate the effects of regulatory changes on risk perceptions and other tobacco-related attitudes; and e) assess differences in attitudes, behaviors, and key health outcomes among racial/ethnic, gender, and age subgroups. The PATH Study will also collect biospecimens from adults to analyze biomarkers of tobacco use and disease processes.

By measuring and accurately reporting on the social, behavioral and health effects associated with tobacco-product use in the U.S., the PATH Study will provide an empirical evidence base to inform the development and assessment of tobacco-product regulations by the FDA.

Other NIH Tobacco-Related Research
NIH funds other tobacco-related research. For a complete portfolio of NIH-supported tobacco research visit the NIH Research Portfolio Online Reporting Tools Expenditures and Results (NIH RePORT) or use the widget below.